Breaking News, Collaborations & Alliances

AMRI Earns Second BMS Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI will receive a $4 million milestone payment from Bristol-Myers Squibb following BMS’s submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AMRI compound licensed to BMS. Upon approval, BMS may begin Phase I testing in Canada.      This compound is a biogenic amine reuptake inhibitor, which may represent a new class of therapeutic agent that could lead to an improved treatment for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters